Nuritas

Use AI to unearth functionally effective peptides from natural ingredients

Contact for pricing Ireland

Nature's proteins hide huge numbers of peptides, of which very few have clear efficacy for the human body. In the past, finding them required slowly screening in a lab, a topic that couldn't be finished in ten years. Nuritas uses AI to first predict which peptides are worth experimenting on, turning finding a needle in a haystack into a directed search.

Features and application scenarios

The core platform is called Nuritas Magnifier, officially described as a proprietary AI system that "identifies, unlocks, and clinically validates smart peptides from nature," having identified over 8 million peptides cumulatively, holding 56 patents, and claiming about an 80% success rate in predicting clinical efficacy. Launched ingredients include the oral PeptiStrong (muscle) and PeptiSleep (sleep), and the topical PeptiYouth and PeptiProtect. Partners include L'Oréal, GNC, Vitamin Shoppe, and Givaudan. The company is headquartered in Dublin, Ireland.

Suited to R&D and procurement in health supplements, functional foods, and cosmetics ingredients. Taiwan's health-supplement market is sizable, but most operators buy ready-made ingredients to make formulas, and very few truly invest in ingredient discovery. Nuritas's model reminds us of one thing: AI's value in biotech isn't replacing experiments but deciding "which experiment to do first" — which is actually more critical for small-to-medium manufacturers with limited R&D budgets. To bring it in, it's mostly in the form of ingredient licensing or contract development.

Main features

Nuritas Magnifier proprietary AI peptide-discovery platform
Over 8 million natural peptides identified
Clinical-efficacy prediction (officially about 80% success rate)
Launched ingredients: PeptiStrong, PeptiSleep, PeptiYouth, PeptiProtect
Customized discovery collaboration for specific health claims

Common uses

Developing new functional ingredients for health supplements
Procurement of topical cosmetic-peptide ingredients
Contract research for specific health claims
Ingredient upgrades for existing formulas

Key Features

Nuritas Magnifier proprietary AI peptide-discovery platform
Over 8 million natural peptides identified
Clinical-efficacy prediction (officially about 80% success rate)
Launched ingredients: PeptiStrong, PeptiSleep, PeptiYouth, PeptiProtect
Customized discovery collaboration for specific health claims

Pros

Has actually launched ingredients and peer-reviewed research, not just staying at the platform stage
Has partnerships with international majors like L'Oréal and Givaudan
Compresses the ingredient-discovery cycle from a decade scale to a plannable project

Cons

Aimed at the B2B ingredient market; general consumers can't buy the platform itself
High collaboration barrier and cost; small manufacturers can't easily take it on alone
Efficacy still needs country-by-country regulatory approval; claims from other countries can't be directly used

Use Cases

Developing new functional ingredients for health supplements
Procurement of topical cosmetic-peptide ingredients
Contract research for specific health claims
Ingredient upgrades for existing formulas

Editor's Note

AI in biotech most easily degenerates into fundraising talk. Nuritas at least actually got ingredients to market — a line many peers haven't crossed.

FAQ

Can Taiwanese manufacturers directly use its ingredients?

PeptiStrong and others are licensable ingredients, but to launch in Taiwan they must still meet Taiwan's food or cosmetics regulations on ingredients and claims. Overseas clinical data doesn't automatically become a usable efficacy claim in Taiwan, so confirm this part with a regulatory consultant first.

Are AI-found ingredients trustworthy?

Nuritas's approach is that AI handles screening and ranking, and it still goes through experimental and clinical validation at the end. The standard for judging credibility isn't how impressive the model it uses is but whether there's peer-reviewed research and human trials — on this it has public data to check.